Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Recruiting · NCT06537843 · Registry updated 2024-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2024-08-05 | NCT06537843 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hospital Amaral Carvalho | Jaú | Brazil | 1 |
| Hospital de Clínicas da UFPR | Curitiba | Brazil | 1 |
| Hospital Municipal Sao Jose | Joinville | Brazil | 1 |
| Hospital Ophir Loyola | Belém | Brazil | 2 |
| Hospital Universitario Polydoro Ernani de Sao Thiago | Florianópolis | Brazil | 1 |